间充质干细胞治疗儿童心血管疾病的研究进展  

Advance of mesenchymal stem cells in the treatment of cardiovascular diseases in children

作　　者：刘庚英(综述) 杜忠东(审校)[1] Liu Gengying;Du Zhongdong(Department of Cardiology,Beijing Children′s Hospital,Capital Medical University,Beijing 100045,China)

机构地区：[1]首都医科大学附属北京儿童医院心内科,100045

出　　处：《国际儿科学杂志》2020年第1期5-8,共4页International Journal of Pediatrics

基　　金：国家自然科学基金(81274109、30973238)。

摘　　要：儿童心肌病、心肌梗死、心力衰竭等心血管疾病的发生率虽不是很高,但因治疗手段有限,往往预后较差,易导致心源性猝死,成为儿童死亡的重要原因之一.近年来,随着干细胞技术和再生医学的迅速发展,干细胞移植已被证实可以促进心肌细胞再生,改善心肌重构,提高左心室射血分数,达到从根源上予以治疗的目的.间充质干细胞是一类多潜能成体干细胞,具有很强的自我更新和多向分化潜能,在再生、组织修复等领域具有广阔的应用前景,目前已经开始应用于心肌病、心肌梗死、心力衰竭等心血管疾病的治疗,并取得了一定的效果.该文就间充质干细胞在儿童心血管疾病的治疗进展方面进行综述.Cardiovascular disease(cardiomyopathy,myocardial infarction,heart failure)seriously endanger child health.Although the incidence in children is not very high,the prognosis is usually poor due to limited treatment options.With the rapid development of stem cell technology and regenerative medicine in recent years,stem cell transplantation has been proved to be able to promote cardiomyocyte regeneration,improve myocardial remodeling and left ventricular ejection fraction(LVEF),so as to alleviate cardiovascular diseases fundamentally.Mesenchymal stem cells(MSCs),a kind of pluripotent adult stem cell with profound self-renewal capacity and multi-directional differentiation potential,have been gradually applied in the treatment of children′s cardiovascular diseases,such as cardiomyopathy,myocardial infarction and end-stage heart failure,and initial success has now been achieved.This review is to summarize the advance of MSCs in the treatment of cardiovascular diseases in children.

关 键 词：间充质干细胞 心血管疾病 儿童 

分 类 号：R54[医药卫生—心血管疾病]